Zai Lab Ltd ADR (ZLAB) Stock Price, Quote & News

Company Profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for commu...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 21 6163 2588

Website: www.zailaboratory.com

Address:

Building B, 899 Halei Road, Pudong, China

Valueforall Aug. 16 at 6:45 PM

$ZLAB @Pika_Capital is correct on the 3-5x multiplier: wall street is mispricing Zai Lab as a legacy licensing boutique while ignoring 8 commercialized assets (including KarXT, TIVDAK, and VYVGART), a proprietary DLL3-ADC pipeline with FDA Fast Track status heading to Phase 3, and $717M+ in cash runway backing an inevitable re-rate!

0 · Reply

Zephix Aug. 13 at 8:56 PM

$ZLAB G2

0 · Reply

Pika_Capital Aug. 7 at 3:13 PM

$ZLAB good timing getting back in 😂

0 · Reply

fda_tracker Aug. 7 at 2:59 PM

$ZLAB New PDUFA Date 2026-11-30 Zai Lab Ltd Link: https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm Calendar: http://www.fdatracker.com/fda-calendar/

0 · Reply

Pika_Capital Aug. 6 at 2:03 PM

$ZLAB got back in at $20 after selling in $30S while back. This can be easy 3-5x if they execute on the pipeline and commercial side

1 · Reply

EarningsInsider Aug. 6 at 1:02 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-zai-lab-limited-stock/ $ZLAB Zai Lab Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 6 at 10:43 AM

$ZLAB Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.50 down -25.00% YoY • Reported revenue of $106.31M down -3.33% YoY

0 · Reply

NasdaqCaptain Aug. 3 at 3:59 PM

$ZLAB FDA granting Orphan Drug Designation for zoci is a meaningful step forward. DLL3-targeting ADCs are targeting a difficult cancer area with limited treatment options, and this adds more validation to Zai Lab’s pipeline potential.

0 · Reply

Laynester Jul. 14 at 11:43 AM

$ALM $PRME $SONY $ZLAB $CF What is going up today in a down market outlook? MATERIALS and HEALTHCARE. Set an alert then stop out....good to all traders everywhere. 100%--->🦬

0 · Reply

FreddieMercury91 Jun. 10 at 8:14 PM

$ZLAB Great day here, monster comeback on the way

1 · Reply

Zai Lab and Argenx announce results from Alkivia Phase 3 study

ARGX

2026-08-17T10:14:51.000Z - 2 days ago

Zai Lab and Argenx announce results from Alkivia Phase 3 study

ARGX

Mon, 17 Aug 2026 06:00:00 -0400 - 2 days ago

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

2026-08-13T13:38:46.000Z - 5 days ago

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

Fri, 07 Aug 2026 17:06:02 -0400 - 11 days ago

Zai Lab Q2 Earnings Call Highlights

2026-08-07T10:51:14.000Z - 12 days ago

Zai Lab price target raised to $45 from $44 at Citi

2026-08-06T14:30:02.000Z - 12 days ago

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Zai Lab Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Zai Lab Earnings release: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Zai Lab Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Zai Lab Slides: Q2 2026

2026-08-06T11:51:37.000Z - 13 days ago

Is Zai Lab Ltd (ZLAB) Positioned for Growth After Q2 Earnings Report? GF Score: 68/100, Revenue ...

2026-08-06T11:00:41.000Z - 13 days ago

Zai Lab reports Q2 EPS (46c), consensus (68c)

Thu, 06 Aug 2026 06:30:00 -0400 - 13 days ago

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

2026-08-03T11:06:23.000Z - 16 days ago

Zai Lab says FDA grants Orphan Drug Designation for zocilurtatug pelitecan

Mon, 03 Aug 2026 07:00:00 -0400 - 16 days ago

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

2026-07-30T11:02:28.000Z - 20 days ago

Zai Lab treatment of neuroendocrine carcinoma granted FDA orphan designation

Wed, 22 Jul 2026 07:30:00 -0400 - 4 weeks ago

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

2026-06-25T05:06:22.000Z - 7 weeks ago

Insider Sell Alert: William Lis Sells 7,040 Shares of Zai Lab Ltd (ZLAB)

Jun 17, 2026, 8:00 AM EDT - 2 months ago

Zai Lab Transcript: AGM 2026

2026-06-16T11:06:24.000Z - 2 months ago

Zai Lab announces EMA granted ODD to zocilurtatug pelitecan

Tue, 16 Jun 2026 07:00:00 -0400 - 2 months ago

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

2026-06-09T12:59:45.000Z - 2 months ago

Zai Lab (ZLAB) Gains Approval for Tivdak in Cervical Cancer Treatment

Mon, 08 Jun 2026 20:34:00 -0400 - 2 months ago

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

2026-06-01T18:42:17.000Z - 2 months ago

Zai Lab (ZLAB) Q1 2026 Earnings Transcript

2026-05-22T07:59:13.000Z - 3 months ago

Zai Lab (ZLAB) Announces Leadership Change Amid Strategic Developments

2026-05-21T22:30:13.000Z - 3 months ago

Zai Lab announces departure of COO Josh Smiley

Thu, 21 May 2026 18:09:00 -0400 - 3 months ago

Zai Lab Announces Changes to Senior Leadership Team

2026-05-16T03:45:03.000Z - 3 months ago

Insider Sell Alert: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB)

2026-05-11T13:57:49.000Z - 3 months ago

Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment

2026-05-11T12:31:26.000Z - 3 months ago

Zai Lab receives FDA Fast Track Designation for zocilurtatug pelitecan

Mon, 11 May 2026 07:00:00 -0400 - 3 months ago

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

Sat, 09 May 2026 05:07:41 -0400 - 3 months ago

Zai Lab Q1 Earnings Call Highlights

2026-05-08T10:37:48.000Z - 3 months ago

Zai Lab price target lowered to $44 from $47 at Citi

ZLAB

2026-05-08T04:09:13.000Z - 3 months ago

Zai Lab (ZLAB) Highlights Strategic Developments and Future Outlook

2026-05-07T15:11:16.000Z - 3 months ago

Zai Lab Q1 2026 Loss Widens to -$0.05/Share, Revenue Down 6%

May 7, 2026, 8:00 AM EDT - 3 months ago

Zai Lab Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Zai Lab Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Zai Lab Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Zai Lab Slides: Q1 2026

2026-05-07T11:02:14.000Z - 3 months ago

Zai Lab reports Q1 EPS (4c), consensus (53c)

2026-05-07T10:52:51.000Z - 3 months ago

Zai Lab Releases Q1 2026 Financial Results

Thu, 07 May 2026 06:00:00 -0400 - 3 months ago

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Zai Lab Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Zai Lab Proxy statement: Proxy filing

Wed, 22 Apr 2026 07:30:00 -0400 - 4 months ago

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

Apr 20, 2026, 8:30 AM EDT - 4 months ago

Zai Lab Transcript: Study update

Apr 20, 2026, 8:30 AM EDT - 4 months ago

Zai Lab Slides: Study update

2026-04-19T18:26:44.000Z - 4 months ago

ZLAB: Zai Lab Unveils Promising Data for ZL-1503 in Treating Atopic Diseases

2026-04-19T17:06:22.000Z - 4 months ago

Zai Lab presents new preclinical data on ZL-1503

Sat, 18 Apr 2026 09:00:00 -0400 - 4 months ago

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

2026-04-17T19:11:20.000Z - 4 months ago

Zai Lab to present zocilurtatug pelitecan clinical data at AACR meeting

Fri, 17 Apr 2026 15:01:00 -0400 - 4 months ago

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Zai Lab Proxy statement: Proxy filing

Wed, 15 Apr 2026 08:00:00 -0400 - 4 months ago

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

2026-04-01T11:47:05.000Z - 5 months ago

Zai Lab, Amgen announces trial agreement to evaluate zocilurtatug pelitecan

AMGN

Wed, 01 Apr 2026 07:30:00 -0400 - 5 months ago

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

2026-03-18T11:28:28.000Z - 5 months ago

Zai Lab price target lowered to $32 from $39 at JPMorgan

Tue, 17 Mar 2026 16:35:00 -0400 - 5 months ago

Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)

2026-02-27T15:21:22.000Z - 6 months ago

Zai Lab price target lowered to $37 from $55 at Cantor Fitzgerald

2026-02-27T11:48:42.000Z - 6 months ago

Zai Lab price target lowered to $47 from $53 at Citi

2026-02-26T13:10:51.000Z - 6 months ago

Zai Lab reports Q4 EPS (46c), consensus (42c)

Feb 26, 2026, 8:00 AM EST - 6 months ago

Zai Lab Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Zai Lab Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Zai Lab Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Zai Lab Slides: Q4 2025

Thu, 26 Feb 2026 07:00:00 -0500 - 6 months ago

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

2026-02-20T11:16:51.000Z - 6 months ago

Zai Lab price target lowered to $53 from $58 at Citi

Feb 19, 2026, 2:30 PM EST - 6 months ago

Zai Lab Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 10, 2026, 8:30 AM EST - 6 months ago

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

2026-02-05T13:36:51.000Z - 6 months ago

Zai Lab price target lowered to $39 from $46 at JPMorgan

Jan 13, 2026, 6:00 PM EST - 7 months ago

Zai Lab Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 6:00 PM EST - 7 months ago

Zai Lab Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:00 AM EST - 7 months ago

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

2026-01-07T13:21:02.000Z - 7 months ago

Zai Lab initiated with a Buy at UBS

Jan 6, 2026, 7:30 AM EST - 8 months ago

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

Jan 5, 2026, 7:30 AM EST - 8 months ago

Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:30 AM EST - 8 months ago

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

Dec 8, 2025, 7:00 AM EST - 9 months ago

Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

Dec 7, 2025, 12:11 AM EST - 9 months ago

Zai Lab Announces Updates to China's National Reimbursement Drug List

Nov 6, 2025, 8:00 AM EST - 10 months ago

Zai Lab Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Zai Lab Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Zai Lab Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Zai Lab Slides: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

Oct 31, 2025, 7:30 AM EDT - 10 months ago

Zai Lab Announces Participation in Investor Conferences in November and December 2025

Oct 24, 2025, 11:00 AM EDT - 10 months ago

Zai Lab Transcript: Study Update

Oct 24, 2025, 11:00 AM EDT - 10 months ago

Zai Lab Press release: Study Update

Oct 24, 2025, 11:00 AM EDT - 10 months ago

Zai Lab Slides: Study Update

Oct 24, 2025, 9:00 AM EDT - 10 months ago

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

Oct 15, 2025, 7:30 AM EDT - 11 months ago

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

Oct 13, 2025, 12:02 PM EDT - 11 months ago

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Sep 9, 2025, 2:35 PM EDT - 1 year ago

Zai Lab Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 10:20 AM EDT - 1 year ago

Zai Lab Transcript: Cantor Global Healthcare Conference 2025

Sep 1, 2025, 8:00 PM EDT - 1 year ago

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

Aug 28, 2025, 7:30 AM EDT - 1 year ago

Zai Lab Announces Participation in Investor Conferences in September 2025

Aug 19, 2025, 7:30 AM EDT - 1 year ago

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

Aug 13, 2025, 11:00 AM EDT - 1 year ago

Zai Lab Establishes Oncology Scientific Advisory Board

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Slides: Q2 2025

Aug 7, 2025, 6:00 AM EDT - 1 year ago

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

Jul 10, 2025, 7:30 AM EDT - 1 year ago

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

Jun 30, 2025, 9:05 AM EDT - 1 year ago

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Jun 13, 2025, 7:00 AM EDT - 1 year ago

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Jun 4, 2025, 10:30 AM EDT - 1 year ago

Zai Lab Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 2:30 PM EDT - 1 year ago

Zai Lab Transcript: American Society of Clinical Oncology Annual Meeting 2025

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Transcript: Status Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Press release: Status Update

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Slides: Status Update

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 1 year ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NVCR

May 30, 2025, 7:30 AM EDT - 1 year ago

Zai Lab Announces Participation in Investor Conferences in June 2025

May 19, 2025, 7:00 AM EDT - 1 year ago

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

May 8, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Slides: Q1 2025

May 8, 2025, 6:00 AM EDT - 1 year ago

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Proxy statement: Proxy Filing

Apr 25, 2025, 1:12 PM EDT - 1 year ago

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Apr 23, 2025, 10:56 AM EDT - 1 year ago

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Apr 21, 2025, 7:30 AM EDT - 1 year ago

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Zai Lab Proxy statement: Proxy Filing

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Mar 12, 2025, 7:30 PM EDT - 1 year ago

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zai Lab Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 7:30 AM EST - 1 year ago

Zai Lab Announces Participation in Investor Conferences in March 2025

Feb 27, 2025, 8:00 AM EST - 1 year ago

Zai Lab Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Zai Lab Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Zai Lab Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Zai Lab Slides: Q4 2024

Feb 27, 2025, 6:00 AM EST - 1 year ago

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Feb 18, 2025, 7:00 PM EST - 1 year ago

Zai Lab Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Jan 28, 2025, 7:30 AM EST - 1 year ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Valueforall Aug. 16 at 6:45 PM

0 · Reply

Zephix Aug. 13 at 8:56 PM

$ZLAB G2

0 · Reply

Pika_Capital Aug. 7 at 3:13 PM

$ZLAB good timing getting back in 😂

0 · Reply

fda_tracker Aug. 7 at 2:59 PM

$ZLAB New PDUFA Date 2026-11-30 Zai Lab Ltd Link: https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm Calendar: http://www.fdatracker.com/fda-calendar/

0 · Reply

Pika_Capital Aug. 6 at 2:03 PM

$ZLAB got back in at $20 after selling in $30S while back. This can be easy 3-5x if they execute on the pipeline and commercial side

1 · Reply

EarningsInsider Aug. 6 at 1:02 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-zai-lab-limited-stock/ $ZLAB Zai Lab Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 6 at 10:43 AM

$ZLAB Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.50 down -25.00% YoY • Reported revenue of $106.31M down -3.33% YoY

0 · Reply

NasdaqCaptain Aug. 3 at 3:59 PM

0 · Reply

Laynester Jul. 14 at 11:43 AM

$ALM $PRME $SONY $ZLAB $CF What is going up today in a down market outlook? MATERIALS and HEALTHCARE. Set an alert then stop out....good to all traders everywhere. 100%--->🦬

0 · Reply

FreddieMercury91 Jun. 10 at 8:14 PM

$ZLAB Great day here, monster comeback on the way

1 · Reply

Spartrap Jun. 10 at 12:53 PM

$ZLAB TIVDAK approved in China yesterday. Yet another drug with $300M+ potential in the commercial offering. Nobody cares! At some point the money will do the talking, and the rise will be f*** meteoric

0 · Reply

SuperGreenToday Jun. 5 at 8:21 PM

$ZLAB Share Price: $16.64 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.75 – $0.92 Potential Upside: 68% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Renzie1 Jun. 5 at 8:53 AM

$ZLAB almost at all time low! Time to load a lot of shares i guess. Average PT is 100% up from cuttent price so... Gl

1 · Reply

Tdorsey1776 May. 22 at 12:36 PM

$ZLAB C suite apocalypse....

1 · Reply

prismmarketview May. 11 at 4:35 PM

$ZLAB Zai Lab Global stock up 7.2% on FDA Fast Track news. 📈 Zoci delivered a 38.2% objective response rate in heavily pretreated patients — and it's now on an expedited path for an aggressive cancer with no approved standard of care. Full breakdown ⤵️ https://prismmarketview.com/zai-lab-stock-jumps-after-fda-grants-fast-track-designation/

0 · Reply

notreload_ai May. 11 at 1:32 PM

$ZLAB drug Zoci got FDA Fast Track for rare cancer epNEC, showing 38% tumor response in early trials, speeding approval path. https://notreload.xyz/xy/zai-lab-zoci-wins-fda-fast-track-for-epnecs/

0 · Reply

AStrokeOfLuck May. 11 at 11:59 AM

$ZLAB

0 · Reply

VCV86 May. 9 at 9:11 PM

$ZLAB Are we expecting any move on Monday after the ARGX approval? It’s been flat after hours.

1 · Reply

MarketBeat May. 9 at 9:06 AM

Zai Lab Q1 Earnings Call Highlights $ZLAB https://www.marketbeat.com/instant-alerts/zai-lab-q1-earnings-call-highlights-2026-05-09/

0 · Reply

Spartrap May. 7 at 11:59 AM

$ZLAB ah shoot, my hopes were way past reality ;-/

2 · Reply

StocktwitsEarnings May. 7 at 10:13 AM

$ZLAB Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.50 down -25.00% YoY • Reported revenue of $99.61M down -6.46% YoY

0 · Reply

Spartrap May. 6 at 9:26 PM

$ZLAB earnings tomorrow. The market is skeptical. I expect good growth but offset by a bit of channel stuffing to reach guidance at the end of 2025. I'd expect $131.5M < x < $133.5M

1 · Reply

Market Cap	2.92B
Revenue (ttm)	460.16M
Net Income (ttm)	-175.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-38.15%
Debt to Equity Ratio	0.39

Volume	1,630,900
Avg Vol	1,000,670
Day's Range	N/A - N/A
Shares Out	113.78M
Stochastic %K	86%
Beta	0.78
Analysts	Strong Sell
Price Target	$36.18